• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Financial Services·SWKHL
Share

SWK Holdings Corporation 9.00% Senior Notes due 2027 Stocks

$ 25.3Last Updated 10.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 192.55M

$ 25.3
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, re

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.07.2026 23:35

HSBC does not expect SpaceX's stock to rise. To value the stock, it had to abandon conventional methods.

24.07.2026 23:10

Freedom recommended buying Alphabet stock after the pullback. What could hinder its growth?

24.07.2026 22:45

Key Developments in the Kazakh Market: The Stakes of the Oil War and Signals from the National Bank

24.07.2026 22:34

"The Divorce of the Century": SK CEO to Pay Ex-Wife $643 Million but Retain Control of SK Hynix

24.07.2026 21:54

A Wake-Up Call That Could Transform the AI Market: What to Look for in Hyperscalers’ Reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026